相关临床试验
26
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1963
进行中（未招募）
1
3.9%
已完成
12
46.1%
尚未招募
2
7.7%
招募中
10
38.5%
撤回
1
3.9%
暂无批准数据
- UNSW Sydney researchers secured $61 million in National Health and Medical Research Council (NHMRC) Investigator Grants across a broad portfolio of medical research projects. - Professor Christopher Goodnow received $3,035,320 to pursue curing autoimmune disease by re-setting the mutated B cell repertoire. - Professor David Thomas and Professor Susan Ramus each received $3,035,320 for precision oncology germline risk management and personalised ovarian cancer classification, respectively. - Additional grants target dementia prevention, congenital heart disease, early cancer detection via liquid biopsy, and PSMA-targeted radionuclide therapy in metastatic prostate cancer.
- Australia's first National Recommendations for Rare Disease Health Care provide eight practical, disease-agnostic actions for clinicians, recognised as an Accepted Clinical Resource by the RACGP. - The UK's NICE published its first rare disease quality standard (QS214) in February 2026, outlining eight quality statements for equitable, person-centred rare disease care. - People living with rare diseases face a "diagnostic odyssey" averaging 4–5 years, with 50% of suspected cases remaining undiagnosed and 95% of rare diseases lacking targeted treatments. - General practitioners are positioned as central coordinators of rare disease care, yet report challenges due to low clinical familiarity, limited evidence, and fragmented health systems.
- Scientists at the Garvan Institute have captured the first-ever real-time video of CD169-positive macrophages attacking and engulfing live melanoma cells using intravital two-photon microscopy. - The study reveals that these macrophages suppress melanoma growth independently of T cells and B cells, challenging the conventional understanding of anti-tumor immunity. - CD169-positive macrophages were also identified in human melanoma tissue samples, concentrated around tumor edges, confirming translational relevance. - The findings point to a potential new therapeutic strategy for "cold tumors" that fail to respond to current immunotherapies, by harnessing or boosting this macrophage population.
- The NSW Government has invested an additional $450,000 in the NSW Early Phase Clinical Trials Alliance (NECTA), bringing total program funding to $975,000 for 2025-2027. - NECTA has successfully increased annual clinical trial availability from 150 to over 180 trials in three years, with more than 800 patients accessing early-stage trials since 2017. - The alliance streamlines patient access through simplified blood-based screening instead of invasive tumor DNA testing, with one in four participants living in regional areas. - A notable success story includes Julian, a stage four metastatic esophageal cancer patient whose tumors shrank to less than a centimeter through NECTA trial access.
- Australian researchers at the Garvan Institute have discovered that romidepsin, an approved lymphoma drug, can overcome treatment resistance in relapsed neuroblastoma by bypassing blocked cellular pathways. - The drug combination triggers cancer cell death through alternative pathways when the standard JNK pathway becomes ineffective, addressing a critical challenge where 9 out of 10 children with recurrent neuroblastoma die. - Animal model studies published in Science Advances showed the romidepsin-chemotherapy combination reduced tumor growth, extended survival, and allowed for lower chemotherapy doses with potentially fewer side effects. - The breakthrough offers new hope for high-risk neuroblastoma cases where 15% of children don't respond to initial treatment and half of responders experience cancer recurrence.
- A Garvan Institute clinical trial found that metformin reduces insulin needs by 12% in type 1 diabetes patients, despite not improving insulin resistance as expected. - The INTIMET study randomized 40 adults with long-term type 1 diabetes to receive either metformin or placebo for six months, using sophisticated clamp studies to measure insulin resistance. - Researchers are now investigating metformin's mechanism of action through gut microbiome studies, as the drug's century-old therapeutic effects remain unexplained. - The findings could improve diabetes management for over 450,000 people with type 1 diabetes in the UK who face significant daily treatment burdens.
- Researchers identified suppression of the JNK signaling pathway, particularly through loss of MAP2K7, as a central mechanism driving resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. - CRISPR/Cas9 knockout screens revealed that MAP2K7 loss disrupts JNK activation and AP-1 transcription factor function, allowing cancer cells to evade stress responses like senescence and apoptosis while maintaining proliferation. - Tumor analysis showed that patients with low JNK pathway activity had poorer prognosis and reduced response to standard therapy, with higher risk of relapse during or after treatment. - The findings suggest JNK pathway assessment could serve as a biomarker for patient stratification, helping clinicians identify patients unlikely to respond to current treatment regimens.
